Sign in
Not yet recruitingNo phase

Utility of Respiratory Biomarker Guidance in Exacerbations

Key facts

Who runs it
Université de Sherbrooke
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
200 people, planned
Starts
1 Jan 2027
Expected to end
28 Feb 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Respiratory pathogen detection via molecular PCR
  • C-reactive protein (CRP) quantification
  • Disclosure of dual POCT results with advisory PCR+CRP algorithm
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (29)Hide the full registry criteria

Who can take part

  • Adults aged ≥18 years at the time of signing the informed consent
  • Presenting to the ED with a clinical diagnosis of asthma or COPD exacerbation, defined as an acute (<14 days) worsening of respiratory symptoms beyond baseline (e.g. increased dyspnea, cough, sputum, or wheezing) requiring urgent evaluation
  • Established diagnosis of asthma or COPD for > 1 month*, based on:
  • For asthma: documented variability in airflow limitation (e.g., spirometric reversibility ≥12% and ≥200 mL in FEV1, or positive bronchial provocation testing), consistent with GINA 2025
  • For COPD: post-bronchodilator FEV1/FVC <0.70 or below the LLN with ≥10 pack-years smoking history and compatible symptoms, consistent with GOLD 2026; *Patients with physician-diagnosed disease, without objective testing, may undergo confirmatory testing < 3 months after URGE trial participation to confirm eligibility
  • Antibiotics were not ordered at the time of randomisation
  • Able to provide signed, informed consent within the ED care window
  • Willingness to undergo molecular microbial PCR and CRP at the point-of-care before antibiotic decision

Who cannot take part

  • Chronic systemic corticosteroid use for any indication. The first systemic corticosteroid dose given before or in the ED for the index exacerbation is permitted and does not constitute exclusion
  • Previous participation in the URGE study (participants may be enrolled only once)
  • Concurrent acute coronary syndrome (either primary or secondary)
  • Vaccination against influenza with FluMist® within 14 days prior; Logistical or Operational Exclusions
  • Medical conditions
  • Current systemic antibiotic for acute respiratory illness at time of evaluation
  • Known significant chronic respiratory disease other than asthma or COPD, including interstitial lung disease, pulmonary hypertension, cystic fibrosis, clinically significant bronchiectasis
  • History of active malignancy within the past 6 months, excluding: non-melanoma skin cancer or localized cervical dysplasia / in situ cancer
  • Significant immunosuppression or ongoing systemic immunosuppressive therapy (e.g., methotrexate or other immunosuppressive disease-modifying antirheumatic drugs (DMARDs), transplant recipients, chemotherapy)
  • End-stage organ disease (e.g., decompensated heart failure, end-stage renal or liver disease)
  • Severe cognitive impairment or inability to provide informed consent
  • Known (test-positive) viral infection within the past 7 days
  • Decompensated heart failure
  • New-onset arrhythmia
  • Clinical concern for sepsis at the time of enrolment: Altered mental status or Systolic blood pressure ≤ 100 mm Hg, unless consistent with the patient's usual baseline and without other signs of hypoperfusion
  • Acute use of non-invasive ventilation (NIV)
  • Pregnancy or breastfeeding
  • Diagnosis of pneumonia with chest X-ray made at the index visit at the clinician's discretion
  • Patient is unable or unwilling to undergo both POCTs
  • Expected discharge to long-term care facility or hospice
  • Patient self-discharges before meeting emergency care physician; Other exclusions; -Individuals are accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalised

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Asthma acute or COPD acute exacerbation

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

People with asthma or chronic obstructive pulmonary disease (COPD) often come to the emergency department because their breathing suddenly gets worse. These flare-ups are called exacerbations. Many of these episodes are caused by viruses or inflammation, not bacteria. However, clinicians still frequently prescribe antibiotics, even when they are unlikely to help. Unnecessary antibiotic use can cause side effects, increase healthcare costs, and contribute to antibiotic resistance, which is a growing public health problem.

Read full original descriptionShow less

The URGE study aims to find a better way to decide when antibiotics are truly needed during asthma or COPD attacks in the emergency department. The study will test whether using two rapid bedside tests can safely reduce unnecessary antibiotic prescriptions.

The first test is a rapid molecular test that looks for common respiratory viruses and certain bacteria using a nasopharyngeal swab. Results are available within about 15 to 20 minutes. The second test measures C-reactive protein (CRP) from a small blood sample. CRP is an inflammation marker that tends to be higher when a bacterial infection is present. Together, these tests give doctors quick information about whether an infection is likely viral, bacterial, or non-infectious.

URGE will recruit 200 adults who come to the emergency department with an asthma or COPD exacerbation to take part in the study. After providing consent, participants will be randomly assigned to one of two groups. In both groups, participants will complete both rapid tests. In one group, the test results will be shared with the treating doctor right away and can be used to help guide treatment decisions. In the other group, the doctor will not see the test results, and care will follow usual practice. Doctors will always be free to make their own clinical decisions, regardless of test results.

The main outcome the study will measure is whether or not patients are prescribed antibiotics when they leave the emergency department or are admitted to hospital. The study will also examine how long patients take antibiotics, hospital admissions, return visits to healthcare services, and patient satisfaction. Participants will be followed up by phone and through medical record review at 7 days and 30 days after their emergency visit to ensure they recover safely.

The URGE trial will study tests that are already approved and commonly used in healthcare. The goal is not to deny needed treatment, but to better match treatment to the cause of the flare-up. If successful, this approach could reduce unnecessary antibiotic use, improve patient care, and support safer, more sustainable treatment of asthma and COPD exacerbations in emergency departments.

The 2 groups in the trial

  • POCT results disclosedTreatment being tested

    Dual POCT results (multiplex PCR + CRP) are disclosed in real time to the treating physician, together with a predefined advisory PCR+CRP antibiotic algorithm; results are communicated to the patient. Clinicians may override the algorithm.

    Treatment: Respiratory pathogen detection via molecular PCR, C-reactive protein (CRP) quantification, and Disclosure of dual POCT results with advisory PCR+CRP algorithm

  • POCT results non disclosedOther group

    Participants undergo the same dual POCT (PCR + CRP) under identical conditions, but results are not disclosed to the treating physician or the participant during the index visit. Usual care per clinician judgment.

    Treatment: Respiratory pathogen detection via molecular PCR and C-reactive protein (CRP) quantification

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Utility of Respiratory Biomarker Guidance in Exacerbations (URGE): a Pragmatic, Randomized, Open-Label, Single-Center Superiority Trial of Dual Point-of-Care Testing to Reduce Antibiotic Use in Adults Presenting to the Emergency Department With Asthma or COPD Exacerbations
Criteria questions
Built from NCT07942298, who can take part
Record updated
17 November 2026